VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

AdsecV
Vaccine Information
  • Vaccine Name: AdsecV
  • Target Pathogen: Yersinia pestis
  • Target Disease: Plague
  • Vaccine Ontology ID: VO_0000827
  • Type: Recombinant vector vaccine
  • V antigen gene engineering:
    • Type: Protein
    • Description:
    • Detailed Gene Information: Click Here.
  • Preparation: The Y. pestis V antigen gene with mammalian-preferred codons was synthesized by overlap polymerase chain reaction and fused to the human Ig signal sequence for extracellular secretion. The V antigen gene was cloned into a recombinant Ad5–based vector (E1a, partial E1b, and partial E3 deletion), to generate AdsecV. AdNull was used as a control vector with identical backbone but no transgene. The vectors were produced in 293 cells and were purified by double CsCl gradient centrifugation. Dosing was based on particle units (pu), the physical number of Ad particles as measured by spectrophotometry. V antigen was purified as a histidine-tag fusion by use of a Ni-NTA Superflow Column (Qiagen) under native conditions (Chiuchiolo et al., 2006).
  • Virulence:
  • Description: Ad vectors are excellent candidates for vaccine platforms as they transfer genes effectively to antigen-presenting cells (APCs) in vivo, with consequent activation of APCs, thus conveying immune adjuvant properties and inducing strong, rapid humoral and cellular immune responses against the transgene product (Chiuchiolo et al., 2006).
Host Response

Mouse Response

  • Host Strain: Female, seven-week old BALB/c mice were obtained from Taconic.
  • Vaccination Protocol: Mice were immunized in a single vaccination by 2 intramuscular injections, with 50 microliter of the vaccine preparation divided evenly between the quadriceps on each side. AdsecV doses ranged from 108 to 1011 pu. Ad vectors were diluted with saline to the specified dose (Chiuchiolo et al., 2006).
  • Persistence: AdsecV induces high IgG titers within 2 weeks after a single immunization (Chiuchiolo et al., 2006).
  • Side Effects: No side effects noted.
  • Challenge Protocol: Four weeks after vaccination, the mice were infected intranasally with 3 × 103 cfu of Y. pestis strain CO92. Assessment of the data at 15 days after challenge showed that the mortality of mice was dependent on the vaccine dose.
  • Efficacy: All of the mice in the group vaccinated with 1011 pu of AdsecV survived the Y. pestis challenge. The 109- and 108-pu doses were not protective; the mice in those groups died according to the same time frame as did the mice in the control groups that received either saline or 1011 pu of AdNull. Thus mice immunized with a single dose of AdsecV are shown to be protected from a lethal intranasal challenge of Y. pestis (Chiuchiolo et al., 2006).
References
Chiuchiolo et al., 2006: Chiuchiolo MJ, Boyer JL, Krause A, Senina S, Hackett NR, Crystal RG. Protective Immunity against Respiratory Tract Challenge with Yersinia pestis in Mice Immunized with an Adenovirus-Based Vaccine Vector Expressing V Antigen. The Journal of infectious diseases. 2006 Nov 1; 194(9); 1249-57. [PubMed: 17041851].